Beyond BRCA: Gene Mutations in Breast Cancer
In just over 5 years, the growth and development in the field of breast cancer have been astronomical. Julie Nangia, MD, Assistant Professor of Medicine, Baylor College of Medicine, discusses the recent explosion of knowledge about non-BRCA genes, and the significant progress in therapies targeted to BRCA mutation carriers.
The differences seen in just over 5 years in regards to the existing knowledge of non-BRCA genes are astronomical. Since then, there has been an explosion of knowledge about other genes, the 3 most common of which are PALB2, CHEK2, and ATM. In addition, Lynch Syndrome, which was thought to only be related to colon cancer shares genes that have been linked to breast cancer.
“The genetic hereditary cancer syndromes are much more complicated than we thought, and there are many, many more genes that would have an impact on how we follow women and potentially can prevent breast cancer in these women,” said Julie Nangia, MD, Assistant Professor of Medicine, Baylor College of Medicine.
Additionally, she says, FDA approval of PARP inhibitors - drugs made for BRCA mutation carriers - have caused a proliferation of research in all tumor types associated with BRCA and other mutations that are in those same pathways. These trials are pursuing treatments that could be less toxic, prevent the need for chemotherapy, and prevent recurrences.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.
